Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006200
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2000-09-09
Brief Title:
Thalidomide and Dacarbazine for Metastatic Melanoma
Sponsor:
National Center for Research Resources NCRR
Organization:
National Center for Research Resources NCRR
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2004-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to assess the activity of thalidomide in combination with dacarbazine DTIC in patients with metastatic melanoma Safety and toxicity of the two drugs will also be assessed Dacarbazine is the standard medical treatment for metastatic melanoma It has been shown to produce tumor shrinkage in approximately 20 of patients with advanced melanoma This shrinkage is usually incomplete and lasts a short time Thalidomide is a drug that inhibits tumor blood vessel growth It can be given orally It is hoped that this combination can be given to patients with metastatic melanoma without causing too much toxicity while increasing the response rate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| M01RR000096 | NIH | None | httpsreporternihgovquickSearchM01RR000096 |